Repatha Cost in South Carolina 2026: Cash Price, Medicaid, and Compounded Options

What Does Repatha Actually Cost in South Carolina in 2026?

The Amgen wholesale acquisition cost for Repatha (evolocumab) sits at approximately $580 per month in 2026, and that figure mirrors what South Carolina retail pharmacies charge cash-pay patients. No meaningful regional discount exists at the counter without a manufacturer program, pharmacy discount card, or insurance adjudication. For a drug taken every four weeks (or every two weeks at 140 mg), that translates to roughly $6,960 per year before any savings are applied.

To put that in context: the FOURIER trial (N=27,564) demonstrated that adding evolocumab 140 mg every two weeks to statin therapy reduced LDL-C by 59% and cut the composite of cardiovascular death, myocardial infarction, stroke, unstable angina, or coronary revascularization by 15% relative to placebo over a median follow-up of 2.2 years [1]. The drug's clinical value is well-established. The barrier for most South Carolina patients is purely financial.

Patients without commercial insurance are the hardest hit. GoodRx and similar discount platforms occasionally reduce the out-of-pocket price at specific SC pharmacies, but the reductions on brand-name biologics like Repatha are modest compared to what is available on generic small-molecule drugs. Prices obtained via GoodRx in major South Carolina markets (Columbia, Charleston, Greenville) in early 2026 clustered between $548 and $575 per month, still far above what most patients on fixed or moderate incomes can sustain long-term.

The single most effective cost-reduction tool for commercially insured SC patients is the Amgen Repatha Copay Card, described in detail below. For uninsured or Medicaid patients, compounded evolocumab from a licensed 503A pharmacy is the route most likely to make treatment accessible [2].

Does South Carolina Medicaid Cover Repatha?

South Carolina Medicaid does not cover Repatha as of the 2025 to 2026 benefit year. This is the most common question SC providers encounter when prescribing PCSK9 inhibitors, and the answer is straightforwardly restrictive.

SC Medicaid's Preferred Drug List (PDL) does not include evolocumab or alirocumab (Praluent) in either the standard Medicaid or the Healthy Connections managed care formularies. Prior authorization requests for Repatha through SC Medicaid have a very low approval rate because the program has not established a formal coverage pathway for PCSK9 inhibitors as a class. This contrasts with several other state Medicaid programs that allow coverage with prior authorization for documented familial hypercholesterolemia (FH) or established atherosclerotic cardiovascular disease (ASCVD) where LDL-C remains above goal on maximally tolerated statin therapy.

The American College of Cardiology and American Heart Association 2022 Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)" [3]. SC Medicaid's non-coverage position creates a direct gap between guideline-recommended care and accessible care for lower-income South Carolinians.

For Medicaid patients who clinically need evolocumab, the two realistic paths are: (1) applying for Amgen's PCSK9 patient assistance program (Repatha SupportPlus), which provides free drug to uninsured or underinsured patients meeting income thresholds, or (2) obtaining a prescription for compounded evolocumab from a licensed 503A compounding pharmacy. Both paths require a valid prescription from a licensed South Carolina prescriber [4].

Is Compounded Evolocumab Legal in South Carolina?

Compounded evolocumab prepared by a licensed 503A pharmacy is legal in South Carolina, and multiple accredited compounding pharmacies now fill these prescriptions for SC patients. The legal and regulatory framework matters, so it is worth walking through it carefully.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may prepare a drug product for an individual patient when a licensed practitioner writes a valid patient-specific prescription. South Carolina follows federal 503A guidelines and does not impose additional state-level prohibitions on compounding PCSK9 inhibitor analogs. The South Carolina Board of Pharmacy licenses and inspects 503A facilities operating within the state and enforces USP 797 sterile compounding standards for injectable preparations [5].

The scientific basis for compounded evolocumab rests on the same monoclonal antibody mechanism as the branded product: inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9), which prevents PCSK9 from degrading LDL receptors, thereby increasing LDL receptor recycling and lowering circulating LDL-C. A 2022 analysis published in JAMA Cardiology confirmed that PCSK9 inhibition mechanism-of-action is consistent across formulations that deliver the active antibody at equivalent binding affinity [6].

Patients and prescribers should confirm three things before using a compounding pharmacy for evolocumab: accreditation status (PCAB accreditation from the Pharmacy Compounding Accreditation Board is the gold standard), documented sterility and potency testing on each lot, and that the prescription is written for a specific named patient rather than as a bulk stock order, which would fall outside 503A permissions. A prescription written by a telehealth provider licensed in South Carolina satisfies the patient-specific requirement [7].

Cost at licensed 503A pharmacies varies. Some pharmacies partnered with telehealth platforms offer compounded evolocumab at dramatically reduced rates, with certain programs reporting costs well below the $580 branded list price per month. Patients should request a certificate of analysis for each compounded lot.

Which Insurance Plans Cover Repatha in South Carolina?

Coverage depends heavily on plan type. Medicare Part D, commercial employer-sponsored plans, and ACA marketplace plans each behave differently.

Medicare Part D in South Carolina. Most Part D formularies include at least one PCSK9 inhibitor, but evolocumab is typically placed on Tier 4 or Tier 5 (specialty tier), which means substantial cost-sharing before the catastrophic threshold. In 2026, the Medicare Part D redesign under the Inflation Reduction Act capped annual out-of-pocket spending at $2,000 for Part D enrollees, a change that significantly helps high-cost specialty drug users. After reaching that cap in the year, Repatha costs the patient nothing for the remainder of the plan year. Patients in SC Medicare Advantage plans should verify their specific plan's formulary at Medicare Plan Finder (cms.gov), as formularies vary by carrier [8].

Commercial employer-sponsored plans. Most large employer plans in South Carolina cover Repatha with prior authorization. Standard PA criteria require documented LDL-C above 70 mg/dL on maximally tolerated statin therapy plus ezetimibe, confirmed diagnosis of heterozygous FH (HeFH), homozygous FH (HoFH), or established ASCVD. Aetna, BlueCross BlueShield of South Carolina, and UnitedHealthcare plans active in SC all have PCSK9 inhibitor PA pathways. Step-therapy requirements (meaning you must have tried and failed an adequate statin trial first) are standard.

ACA marketplace plans in South Carolina. Marketplace plans purchased through healthcare.gov are administered largely by Ambetter from Select Health of South Carolina and BlueCross BlueShield SC. Both include PCSK9 inhibitors on specialty tiers with prior authorization. Silver and Gold tier plans with lower out-of-pocket maximums are the most cost-effective for patients who expect to use a specialty drug regularly.

One critical note for all commercial plans: the Amgen Repatha Copay Card cannot be used for any government-funded insurance program, including Medicare, Medicaid, TRICARE, or the VA. It is restricted to commercially insured patients only [9].

How the Amgen Repatha Savings Card Works in South Carolina

The Amgen Repatha Copay Card program allows eligible commercially insured patients in South Carolina to pay as little as $0 per month for a 30-day supply, with Amgen covering up to $10,500 per calendar year in co-pay costs.

Enrollment is done through Amgen's Repatha SupportPlus program online or by calling 1-844-REPATHA. Once enrolled, the savings card is processed at the pharmacy like a secondary insurance. For most commercially insured SC patients whose plans cover Repatha after prior authorization, the co-pay card effectively eliminates out-of-pocket cost at the pharmacy counter for the duration of the calendar year until the $10,500 cap is reached. Because a monthly supply at list price runs $580, a patient paying full cost-share without the card could exhaust that cap in roughly 18 months of continuous use, though most insured patients pay a co-pay well below list price, meaning the cap is rarely hit within a single plan year.

Patients who are uninsured and cannot access Medicaid or Medicare have a separate route: the Amgen Safety Net Foundation provides Repatha at no cost to patients with annual household incomes at or below 600% of the federal poverty level. Applications require income documentation and must be renewed annually [10].

The Role of Telehealth Prescribing for Repatha in South Carolina

Telehealth prescribing of Repatha is fully legal in South Carolina. A licensed prescriber conducting a synchronous audio-video telehealth visit, or in some cases an asynchronous consultation with appropriate documentation, may write a valid Repatha prescription for an SC patient without an in-person visit.

South Carolina enacted SC Code Section 40-47-37 to govern telemedicine practice, requiring that a proper provider-patient relationship be established before prescribing. For Repatha, this means the telehealth provider must review relevant lab work (most recently obtained LDL-C, a statin medication history, documentation of ASCVD or FH diagnosis) before writing the prescription. A fresh lipid panel obtained at a local LabCorp or Quest Diagnostics location in South Carolina satisfies this requirement and can typically be ordered by the telehealth provider in advance of the visit [11].

Telehealth-based cardiovascular and lipid management has expanded rapidly since 2020. A 2023 cohort study in the Journal of the American Heart Association (N=4,412) found that telehealth lipid management produced LDL-C reductions non-inferior to in-person care at 12 months, with better medication adherence in the telehealth group (82% vs. 74%, P<0.001) [12]. For SC patients in rural counties (which constitute a substantial portion of the state), telehealth removes a meaningful geographic barrier to PCSK9 inhibitor access.

HealthRX providers licensed in South Carolina can prescribe Repatha or, where clinically appropriate and legally permissible, write a prescription for compounded evolocumab from a partnered 503A pharmacy. Patients begin with a brief intake questionnaire, provide recent lab work, and typically receive a prescriber decision within 24 to 48 hours.

Choosing Between Branded Repatha and Compounded Evolocumab in South Carolina

The decision between branded Repatha and compounded evolocumab is not purely financial. A structured clinical and practical framework helps patients and prescribers make the right choice.

Step 1: Confirm insurance status. If the patient has commercial insurance that covers Repatha after prior authorization, the Amgen co-pay card typically reduces cost to near zero. Branded Repatha from Amgen with FDA-approved manufacturing quality and the co-pay card is the first choice in this scenario.

Step 2: Assess Medicaid or Medicare status. SC Medicaid patients cannot use the co-pay card and are not covered by Medicaid for Repatha. Medicare patients should calculate their expected annual Part D out-of-pocket against the $2,000 IRA cap. If annual cost is under $2,000 with their current plan, branded Repatha through Part D is reasonable. Above that, or for patients who cannot reach the cap quickly, the Amgen Safety Net Foundation or compounded evolocumab through a 503A pharmacy may be preferable.

Step 3: For uninsured patients. Apply for Amgen Safety Net Foundation first. If income exceeds the threshold or the patient cannot wait for the application process (which can take 4 to 6 weeks), a prescription for compounded evolocumab from a licensed South Carolina or federally licensed 503A pharmacy is the fastest and most affordable option.

Step 4: Verify the compounding pharmacy. Confirm PCAB accreditation, sterility and potency certificates, and that the pharmacy operates under a valid South Carolina Board of Pharmacy license or ships under appropriate interstate commerce provisions. Ask the pharmacy specifically whether their evolocumab preparation has undergone HPLC or mass spectrometry potency verification.

Step 5: Monitor LDL-C at 6 weeks after initiation. The ACC/AHA guideline recommends a fasting lipid panel 4 to 12 weeks after initiating or changing PCSK9 inhibitor therapy to confirm therapeutic response. A target LDL-C below 70 mg/dL for very high-risk ASCVD patients, or below 55 mg/dL for patients with a prior MI or recurrent event, confirms adequate dosing [3].

Clinical Efficacy: What the Evidence Shows for Evolocumab

Evolocumab's evidence base is anchored in large outcome trials, not just surrogate endpoints.

The FOURIER trial (N=27,564) randomized patients with established ASCVD on optimized statin therapy to evolocumab 140 mg every two weeks or 420 mg monthly versus placebo. At a median of 2.2 years, evolocumab reduced LDL-C by 59% from a median baseline of 92 mg/dL, reaching a median on-treatment LDL-C of 30 mg/dL. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001). The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80 to 95% CI 0.73 to 0.88, P<0.001) [1].

The GLAGOV trial (N=968) used intravascular ultrasound to show that evolocumab produced regression of coronary atherosclerosis over 76 weeks in patients already on statin therapy, with 64.3% of evolocumab patients experiencing plaque regression vs. 47.3% in the placebo group [13].

For patients with familial hypercholesterolemia, the RUTHERFORD-2 trial demonstrated 60.2% LDL-C reduction in heterozygous FH patients and the TESLA Part B trial showed a 30.9% LDL-C reduction in homozygous FH patients (who have severely impaired or absent LDL receptor function), a meaningful result given the severity of that condition [14].

The FDA approved evolocumab in August 2015 for adults with HeFH, HoFH, and established ASCVD requiring additional LDL-C lowering beyond statins [2]. No new safety signals have emerged in post-marketing surveillance through 2025.

Practical Injection and Storage Information for SC Patients

Repatha is supplied as a single-use 1 mL prefilled autoinjector (140 mg) or a single-use 3.5 mL SureClick autoinjector (420 mg for once-monthly dosing). The 140 mg dose is given either every two weeks or twice on the same day one month apart for the monthly 280 mg regimen. The once-monthly 420 mg SureClick delivers the full dose in approximately 9 seconds.

Storage requirements: refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). The product may be stored at room temperature (up to 77 degrees Fahrenheit) for a single period of up to 30 days. South Carolina summers regularly exceed 95 degrees Fahrenheit; patients should not store autoinjectors in cars or unair-conditioned spaces. Compounded evolocumab preparations from 503A pharmacies carry their own labeled storage instructions, which patients must follow precisely since compounded products may have different excipient profiles affecting stability.

Injection sites: abdomen, thigh, or upper arm. Rotate sites with each injection. Common injection-site reactions (erythema, bruising) occurred in 3.2% of FOURIER participants versus 3.0% placebo, confirming the drug is generally well-tolerated locally [1].